- Home
- PD vs VRDN Comparison
PD vs VRDN Comparison
Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- VRDN
- Stock Information
- Founded
- PD 2009
- VRDN 2006
- Country
- PD United States
- VRDN United States
- Employees
- PD N/A
- VRDN N/A
- Industry
- PD Computer Software: Prepackaged Software
- VRDN Medical Specialities
- Sector
- PD Technology
- VRDN Health Care
- Exchange
- PD Nasdaq
- VRDN Nasdaq
- Market Cap
- PD 1.7B
- VRDN 1.5B
- IPO Year
- PD 2019
- VRDN N/A
- Fundamental
- Price
- PD $18.29
- VRDN $18.13
- Analyst Decision
- PD Buy
- VRDN Buy
- Analyst Count
- PD 11
- VRDN 12
- Target Price
- PD $22.09
- VRDN $36.44
- AVG Volume (30 Days)
- PD 1.1M
- VRDN 1.5M
- Earning Date
- PD 03-13-2025
- VRDN 02-25-2025
- Dividend Yield
- PD N/A
- VRDN N/A
- EPS Growth
- PD N/A
- VRDN N/A
- EPS
- PD N/A
- VRDN N/A
- Revenue
- PD $457,170,000.00
- VRDN $302,000.00
- Revenue This Year
- PD $11.41
- VRDN $2.55
- Revenue Next Year
- PD $9.97
- VRDN N/A
- P/E Ratio
- PD N/A
- VRDN N/A
- Revenue Growth
- PD 8.71
- VRDN N/A
- 52 Week Low
- PD $16.46
- VRDN $11.40
- 52 Week High
- PD $26.60
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PD 45.60
- VRDN 44.39
- Support Level
- PD $18.13
- VRDN $16.60
- Resistance Level
- PD $19.00
- VRDN $21.58
- Average True Range (ATR)
- PD 0.62
- VRDN 1.00
- MACD
- PD 0.10
- VRDN -0.16
- Stochastic Oscillator
- PD 64.32
- VRDN 30.72
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its platform harnesses digital signals from virtually any software-enabled system or device and combines it with human response data to take the right actions in real-time. The product offerings of the company include PagerDuty Incident Management, DevOps, AIOPs, Process Automation, and Customer Service Operations.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.